Antibodies to the Buried N Terminus of Rhinovirus VP4 Exhibit Cross-Serotypic Neutralization
- 15 July 2009
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 83 (14), 7040-7048
- https://doi.org/10.1128/jvi.00557-09
Abstract
Development of a vaccine for the common cold has been thwarted by the fact that there are more than 100 serotypes of human rhinovirus (HRV). We previously demonstrated that the HRV14 capsid is dynamic and transiently displays the buried N termini of viral protein 1 (VP1) and VP4. Here, further evidence for this “breathing” phenomenon is presented, using antibodies to several peptides representing the N terminus of VP4. The antibodies form stable complexes with intact HRV14 virions and neutralize infectivity. Since this region of VP4 is highly conserved among all of the rhinoviruses, antiviral activity by these anti-VP4 antibodies is cross-serotypic. The antibodies inhibit HRV16 infectivity in a temperature- and time-dependent manner consistent with the breathing behavior. Monoclonal and polyclonal antibodies raised against the 30-residue peptide do not react with peptides shorter than 24 residues, suggesting that these peptides are adopting three-dimensional conformations that are highly dependent upon the length of the peptide. Furthermore, there is evidence that the N termini of VP4 are interacting with each other upon extrusion from the capsid. A Ser5Cys mutation in VP4 yields an infectious virus that forms cysteine cross-links in VP4 when the virus is incubated at room temperature but not at 4°C. The fact that all of the VP4s are involved in this cross-linking process strongly suggests that VP4 forms specific oligomers upon extrusion. Together these results suggest that it may be possible to develop a pan-serotypic peptide vaccine to HRV, but its design will likely require details about the oligomeric structure of the exposed termini.Keywords
This publication has 26 references indexed in Scilit:
- A part of the VP4 capsid protein exhibited by coxsackievirus B4 E2 is the target of antibodies contained in plasma from patients with type 1 diabetesJournal of Medical Virology, 2008
- Pocket Factors Are Unlikely To Play a Major Role in the Life Cycle of Human RhinovirusJournal of Virology, 2007
- VP1 Sequencing of All Human Rhinovirus Serotypes:Insights into Genus Phylogeny and Susceptibility to AntiviralCapsid-BindingCompoundsJournal of Virology, 2004
- Human Rhinovirus Type 16: Mutant V1210A Requires Capsid-Binding Drug for Assembly of Pentamers To Form Virions during MorphogenesisJournal of Virology, 2003
- Genome Delivery and Ion Channel Properties Are Altered in VP4 Mutants of PoliovirusJournal of Virology, 2003
- Structure of human rhinovirus serotype 2 (HRV2)11Edited by R. HuberJournal of Molecular Biology, 2000
- Human rhinovirus 3 at 3.0 å resolutionStructure, 1996
- Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyonNature, 1996
- The structure of human rhinovirus 16Structure, 1993
- Myristylation of picornavirus capsid protein VP4 and its structural significanceNature, 1987